🎉 Founding Member Beta — Join our Discord and get 3 months of Pro free. Learn more →

Steven Cohen’s CNTX Holdings & Trades

First Buy
Q4 2025
Duration Held
2 Quarters
Largest Add
Q4 2025
+52,701 Shares
Current Position
57,231 Shares
$149,945 Value

Steven Cohen's CNTX Position Overview

Steven Cohen (via Point72 Asset Management, L.P.) currently holds 57,231 shares of Context Therapeutics Inc. (CNTX) worth $149,945, representing 0.00% of the portfolio. First purchased in 2025-Q4, this recently established position has been held for 2 quarters.

Based on recent 13F filings, Steven Cohen has initiated a new position in CNTX, representing a fresh investment thesis on this company. Largest addition occurred in Q1 2026, adding 4,530 shares.

Analysis based on 13F filings available since 2013 Q2

Steven Cohen's Context Therapeutics (CNTX) Holding Value Over Time

Track share changes against reported price movement

Quarterly Context Therapeutics (CNTX) Trades by Steven Cohen

Report Date Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q1 2026 +4,530 Add 8.60% 57,231 $2.62
Q4 2025 +52,701 New Buy 52,701 $1.47

Steven Cohen's Context Therapeutics Investment FAQs

Steven Cohen first purchased Context Therapeutics Inc. (CNTX) in Q4 2025, acquiring 52,701 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Steven Cohen has held Context Therapeutics Inc. (CNTX) for 2 quarters since Q4 2025.

Steven Cohen's largest addition to Context Therapeutics Inc. (CNTX) was in Q4 2025, adding 52,701 shares worth $77,470.

According to the latest 13F filing for Q1 2026, Steven Cohen's firm, Point72 Asset Management, L.P., owns 57,231 shares of Context Therapeutics Inc. (CNTX), valued at approximately $149,945.

As of the Q1 2026 filing, Context Therapeutics Inc. (CNTX) represents approximately 0.00% of Steven Cohen's publicly disclosed stock portfolio, making it one of their key holdings.

Steven Cohen's peak holding in Context Therapeutics Inc. (CNTX) was 57,231 shares, as reported at the end of Q1 2026.